Saanso Pharma Profile
Key Indicators
- Authorised Capital ₹ 16.00 Cr
as on 07-07-2024
- Paid Up Capital ₹ 14.90 Cr
as on 07-07-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 38.21 Cr
as on 07-07-2024
- Revenue %
(FY 2022)
- Profit -47.36%
(FY 2022)
- Ebitda -24.79%
(FY 2022)
- Net Worth -1.52%
(FY 2022)
- Total Assets 13.67%
(FY 2022)
About Saanso Pharma
The Corporate was formerly known as Genesis I.B.R.C. Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 16.00 Cr and a paid-up capital of Rs 14.90 Cr.
The company currently has active open charges totaling ₹38.21 Cr.
Pruthvi Krishna, Vamse Ratnakaram, and Siva Naren serve as directors at the Company.
- CIN/LLPIN
U01409AP2017PTC105626
- Company No.
105626
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Eluru, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Saanso Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pruthvi Krishna  | Director | 01-Feb-2023 | Current |
| Vamse Ratnakaram | Director | 22-Feb-2023 | Current |
| Siva Naren | Director | 01-Feb-2023 | Current |
Financial Performance and Corporate Structure Insights of Saanso Pharma.
Saanso Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 47.36% decrease in profit. The company's net worth dipped by a decrease of 1.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saanso Pharma?
In 2022, Saanso Pharma had a promoter holding of 64.75% and a public holding of 35.25%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Adithya Commercials (India) Private LimitedActive 4 years 9 months
Pruthvi Krishna is a mutual person
- Omics Biosciences Private LimitedActive 2 years 10 months
Pruthvi Krishna and Siva Naren are mutual person
- Saanso Life Sciences Private LimitedActive 2 years 1 month
Vamse Ratnakaram and Siva Naren are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Dec 2023 | ₹38.00 Cr | Open |
Hdfc Bank Limited Creation Date: 07 Feb 2022 | ₹2.06 M | Open |
How Many Employees Work at Saanso Pharma?
Saanso Pharma has a workforce of 12 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saanso Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saanso Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
